Skip to content

A post-market, observational study to Evaluate the Efficacy and Safety of Enterovirus Type 71 Inactivated Vaccines (human diploid cell) in large population

A post-market, observational study to Evaluate the Efficacy and Safety of Enterovirus Type 71 Inactivated Vaccines (human diploid cell) in large population

Status
Recruiting
Phases
Phase 4
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-OIC-16009180
Enrollment
Unknown
Registered
2016-09-10
Start date
2016-09-15
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hand, foot and mouth disease (HFMD)

Interventions

intervention group:2 dose of EV71 vaccine for 28 days interval

Sponsors

Hubei provincial center for disease control and prevention
Lead Sponsor

Eligibility

Sex/Gender
All
Age
0.5 Years to 6 Years

Inclusion criteria

Inclusion criteria: 1. Healthy males and females, aged from 6 months to 71 months on the day of enrollment; 2. Healthy male or female judged by a self-reported medical history, physical examination and clinical judgment and who complies with vaccination of this product; 3. Subjects parent(s) or legal guardian(s) of Subjects are able to understand this study and willing to comply with all study requirements; 4. Subjects parent(s)/legal guardian(s) of Subjects are able to understand and sign informed consents.

Exclusion criteria

Exclusion criteria: 1. Be allergic to the vaccine's active substance , any inactive substance or material used in preparation processes ,include excipients ,formaldehyde and kanamycin sulfate; 2. Have a fever or acute illness; 3. Have serious chronic diseases or allergies.

Design outcomes

Primary

MeasureTime frame
incidence of adverse reactions;

Secondary

MeasureTime frame
morbidity of HFMD;index of effectiveness;

Countries

China

Contacts

Public ContactGuan Xuhua

Hubei provincial center for disease control and prevention

guanxh9999@163.com+86 27 87652170

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026